News Despite Trump price concerns, JP Morgan event anticipates M&... 2017 could be a bumper year for M&A - but Trump's price control threats dominate
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News Sanofi outbids J&J for Actelion merger - reports Reports suggest Sanofi could pay $30 billion for Swiss biotech.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.